How Sichuan Medicine Abandons "Inertness" and Embraces Innovation

　　This reporter Zhou Wei August 11, composed of 20 provincial CPPCC members, "our province's high-end medical equipment and drug production" research group first station into Kanghong Pharmaceuticals, the company's chairman Ke Zunhong introduced, their company spent 10 years, spent 1 billion yuan of independent research and development of Compaxipu, to fill the gap in similar drugs, it is expected that the future is tens of billions of yuan of market imagination space.　　In contrast, an old-fashioned Chinese medicine called "Fufang Danginseng tablets", there are 792 pharmaceutical plants in the country in production, which also includes many Sichuan pharmaceutical companies, in addition to a enterprises is original, the remaining 791 pharmaceutical companies are imitation, and such a huge amount of production led to the drug of the production of excess production and enterprises vicious competition "Under the guidance of the hospital bidding 'only low-price winning bid' policy, enterprises kill each other, and even the winning bid price is lower than the cost price Xue Yongjiang, president of Enway Group, revealed "Drug research and development can not just engage in me-too (generic), innovation is the right way, in order to lead Sichuan medicine out of the country, break the embarrassment of China's pharmaceutical exports "The members of the provincial CPPCC at the meeting have believed that the Sichuan pharmaceutical industry should take the initiative to adapt to the provincial committee, the provincial government to implement the "
innovation drive development" strategy, increase scientific research input and technical public relations, put an end to low-end homogenous production, cut into the high-end industry, shape high-end "Chuan medicine" brand.　　It is understood that age-related macular degeneration is one of the three general blind factors in the world, the incidence of people over 60 years of age in China more than 10% Prior to Compaxirp's introduction, therapeutic drugs had relied on imports, were expensive and injected more frequently "Similar imported drugs need to be injected one monthly, the price of about 10,000 yuan each, and Compaxipu can be injected once in February-March, and each price is more than 6000 yuan, both cost and efficacy are better than foreign." Kanghong Pharmaceutical Group related person in charge revealed that this new drug will become the company's future performance of the emerging support point.　　On the same day's research symposium, Curran Pharmaceuticals, Mike Bio, Good Doctor Pharmaceuticals and other 10 "Chuan Pharmaceutical" leading enterpriseleaders have revealed their own development ambitions and practical difficulties "Pharmaceutical innovation costs and risks are enormous, new drugs research and development will invest heavily, and from research and development to the market, not a decade or eight years, and once difficult to go on the market, for enterprises will be 'bloodless', and may even affect the survival of enterprises." Sichuan Nangel Biotech, the relevant person in charge said that the slow clinical approval of new drugs is a bottleneck restricting innovation in pharmaceutical companies It is also because of this, leading to the vast majority of China's pharmaceutical enterprises are chasing the pace of foreign enterprises, waiting for the expiration of patented drugs after a large number of generic drugs, over time formed an industry "inert".　　Happily, these development bottlenecks are about to be solved According to the provincial government's "Implementation Opinion to Accelerate the Innovation and Development of the Pharmaceutical Industry", a reward of up to 5 million yuan shall be given to the first time in Sichuan industrialization of drugs that have obtained the national new drug certificate, and a certain amount of risk compensation shall be given after the innovation failure of the investment country's 1 st 2 new drugs, and the research and development of a single project has invested more than 10 million yuan At the same time, aiming at the goal of the full-caliber pharmaceutical industry to reach 500 billion yuan in 2020, the Opinion puts forward seven key work plans, covering joint innovation, technological upgrading, chinese medicine development, emerging industries, market circulation, personnel training, open cooperation and so on For example, for the long research and development cycle, investment in large issues, "to the new drug pre-clinical and clinical stage of the creation of research and development phased support, the completion of clinical trials I, II, III, respectively, according to the current proportion of research and development costs to be subsidized." "Quick evaluation allows patients to enjoy the well-being of pharmaceutical innovation As a special commodity of medicine, it has a more important significance and role in people's health and quality of life than other commodities The development of the pharmaceutical industry not only affects the survival and development of production and marketing enterprises, but also is a major event related to the people's livelihood.　　For a long time, due to the lack of innovation ability in the domestic pharmaceutical industry, some chronic diseases, major diseases of the treatment of drugs are not effective, have to rely on imported drugs However, the prices of imported medicines are often too high, adding a great financial burden to patients.　　Lu Yong, a leukaemia patient who has aroused wide public concern, was arrested for buying special effects drugs from abroad, leaving aside the legal aspect, and from another side also reflected the serious imbalance between patient demand and market supply It is understood that Lu Yong purchased the drug of goods called Grewe, is a treatment of slow-grain leukemia special effects, because the price of this patented drug and foreign drugs the same generic drug price there is a hundred times the difference, and there is no generic drug, resulting in the "Lu Yong case" produced.　　However, it is gratifying to note that the advent of the new drug, to age-related macular degeneration patients brought the gospel, "the same kind of imported drugs need to inject one a month, the price of about 10,000 yuan each, and Compaxip can be injected in February-March, and each price of more than 6000 yuan, both cost and efficacy are better than foreign." "This innovation of Kanghong Pharmaceutical Group, which has been on the market for less than a year, has brought light and hope to tens of thousands of patients.　　Why is the number of innovative new drugs in China small? It is understood that, because of the cost of innovation and great risks of pharmaceutical enterprises, do not do well will be "bloodless", and may even affect the survival of enterprises, which to a large extent affected the innovation enthusiasm of pharmaceutical companies Facing the huge demand for innovative new drugs and the golden opportunity of industrial development, the provincial government issued the Implementation Opinion on Speeding up the Innovation and Development of the Pharmaceutical Industry, and decided to give financial incentives or risk compensation for the first time in Sichuan industrialization, innovation failure, such as drugs that have obtained the national new drug certificate, and encourage enterprises to innovate boldly We believe that, with the help of market-driven and policy-protected, pharmaceutical companies are also ushering in a golden period of their own development while providing patients with more and cheaper innovative new drugs.　　(Xiaohua)